NASH
Selected indexed studies
- NAFLD and NASH: etiology, targets and emerging therapies. (Drug Discov Today, 2024) [PMID:38301798]
- Triggering and resolution of inflammation in NASH. (Nat Rev Gastroenterol Hepatol, 2018) [PMID:29740166]
- Current treatment paradigms and emerging therapies for NAFLD/NASH. (Front Biosci (Landmark Ed), 2021) [PMID:33049668]
_Worker-drafted node — pending editorial review._
Connections
NASH is caused by
Sources
- NAFLD: Mechanisms, Treatments, and Biomarkers. (2022) pubmed
- NAFLD and NASH: etiology, targets and emerging therapies. (2024) pubmed
- Triggering and resolution of inflammation in NASH. (2018) pubmed
- Current treatment paradigms and emerging therapies for NAFLD/NASH. (2021) pubmed
- Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances. (2023) pubmed
- Immune cell-mediated features of non-alcoholic steatohepatitis. (2022) pubmed
- TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism. (2020) pubmed
- Nonalcoholic Steatohepatitis: A Review. (2020) pubmed
- Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. (2020) pubmed
- NFATc4: New hub in NASH development. (2020) pubmed